Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma

G. Schiller, R. Vescio, C. Freytes, G. Spitzer, M. Lee, C. H. Wu, J. Cao, J. C. Lee, A. Lichtenstein, M. Lill, R. Berenson, J. Berenson

Research output: Contribution to journalArticlepeer-review

52 Scopus citations

Abstract

Fifty-five patients with advanced multiple myeloma received purified CD34-selected peripheral blood progenitor cell transplants following myeloablative chemotherapy. A median of 4.1 x 106 CD34 cells/kg (range 1.2-30.7) were infused after busulfan (14 mg/kg) and cyclophosphamide (120 mg/kg); granulocyte-macrophage colony-stimulating factor was used until hematopoietic recovery. Median time to neutrophils > 0.5 x 109/l and platelets > 20 x 109/l were 12 days (range 10-16 and 8-184 days, respectively). Median follow-up of survivors from the time of transplantation is 33 months (range 7 to 44 months). Thirty-one patients are alive, 19 progression-free. Median progression-free survival is 14 months. Actuarial 3-year progression-free and overall survival are 29 ± 14% and 47 ± 17%. CD34-selection of peripheral blood progenitor cells provides effective hematopoietic support with significant progression-free and overall survival.

Original languageEnglish (US)
Pages (from-to)141-145
Number of pages5
JournalBone Marrow Transplantation
Volume21
Issue number2
DOIs
StatePublished - Jan 2 1998

Keywords

  • CD34-positive stem cells
  • Multiple myeloma
  • Transplantation

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint Dive into the research topics of 'Autologous CD34-selected blood progenitor cell transplants for patients with advanced multiple myeloma'. Together they form a unique fingerprint.

Cite this